INTEGRATIVE INSIGHTS
ON EMERGING OPPORTUNITIES

Integrative research means our extensive company research informs every thesis and perspective. The result is deep industry knowledge, expertise, and trend insights that yield valuable results for our partners and clients.

About the Author:
Joseph Munda
Senior Vice President
Joe Munda has worked in finance and investment for 16 years and joined First Analysis in 2015. He works with entrepreneurs as an investor and as an advisor on growth transactions to help build leading businesses in healthcare technology. He has played a key role in building First Analysis’s franchises in drug development technology and medical technology and has published several thought-leading white papers in those areas. He serves on the board of VIDA Diagnostics. Prior to joining First Analysis, he was an equity research analyst covering medical device and healthcare services companies at Sidoti & Co. Earlier, he worked in institutional sales at Bear Stearns/J.P. Morgan. He earned a bachelor's degree in finance from Fairleigh Dickinson University.
First Analysis Pharma IT Team
Joseph Munda
Senior Vice President
Matthew Nicklin
Managing Director
Tracy Marshbanks
Managing Director
Andrew Walsh
Managing Director
Pharma IT
Technology is key in medical affairs’ rise as pharma’s third pillar
March 1, 2022
  • The pharmaceutical industry’s shift away from dependence on sales reps for commercialization, the broad evolution of healthcare in recent decades, and the effects of the pandemic on healthcare practices have set the stage for pharma companies’ medical affairs (MA) function to join commercialization and research and development as a key pillar of the industry. MA addresses the need to inform, sitting at a pivotal intersection in pharma and serving as an internal bridge between research and development and commercialization as well as a bridge between pharma companies and their external stakeholders.
  • Technology has been a key factor behind MA’s emergence as pharma’s third pillar. Digital tools have enabled MA to derive and communicate meaningful insights and evidence from the huge and complex mass of scientific data generated by the healthcare system. These tools continue to evolve, further empowering MA and making it even more effective as one of the three pillars.
  • We discuss three areas where innovative technology companies are delivering powerful new tools for MA personnel: finding key opinion leaders, engaging and collaborating virtually, and generating insights and evidence. For each, we highlight some of the technology providers that offer compelling solutions.

TABLE OF CONTENTS

Includes discussion of eight private companies

A brief history of medical affairs

Technology among several factors making MA the third pillar

Finding key opinion leaders

Virtual engagement and collaboration

Insights and evidence generation

Powerful technologies strengthen pharma's third pillar

eClinical index lead over S&P 500 narrows; commercialization index turns negative

Pharma IT M&A pace remains strong

Pharma IT private placement pace accelerates from Q3 low

A brief history of medical affairs

Medical affairs got its start as a key pharma function in 1967 at Upjohn (now part of Viatris, VTRS). The increasing complexity of drugs led the company to rethink how it engaged and communicated with healthcare providers. It launched a technically sophisticated team of field personnel to work with sales representatives to improve the image of the company in the eyes of both clinical researchers and key opinion leaders. These medical science liaisons (MSLs), as they are known, employed a face-to-face strategy rooted in education to better understand the needs of Upjohn’s customers and leverage the insights gleaned to enhance the company’s product development strategy. With time and broad adoption throughout the industry, the model evolved into the medical affairs team – a team of scientifically and medically trained personnel who are experts in communicating complex therapeutic scientific and medical information to a variety of stakeholders.

To access the full report, please provide your contact information in the form below. A First Analysis representative will follow up with you shortly. Thanks for your interest in First Analysis research.
First Name required!
Last Name required!
Email required!
Industry required!
Unfortunately, your request to access the complete report has failed.

Please check the contact information you have entered.

If the form submission failure persists, please contact Person at (xxx) xxx-xxxx to handle your request. Thank you.
©2022 by First Analysis Corporation.
One South Wacker Drive
  ·  
Suite 3900
  ·  
Chicago, IL 60606
  ·  
312-258-1400